Citations

Clear

3138 citation(s) found for "Smith, AM".

Carpometacarpal Boss: An Unusual Cause of Extensor Tendon Ruptures
Ladak, Adil , Shin, Alexander Y. , Smith, Jay , Spinner, Robert J. , Shin, Alexander Y

Mayo Clinic

HAND | March 10, 2014 | Volume: 10 | Issue: 1 | Pages: 155-158

10.1007/s11552-014-9623-0 | PMID 25762892 Get It

Associations Among Fluid Intake, Cognitive Function, and Length of Stay in Psychogeriatric Inpatients
Archer, Sarah J., Barna, Amy E., Holper, Roxanna M., Forsyth, Diane McNally, Ellenbecker, Susan M., Smith, Linda K., Clobes, Jane E., Malone, Chris, Meiers, Sonja J. , Malone, Christopher B., Lapid, Maria I.

Mayo Clinic

Perspectives in Psychiatric Care | March 8, 2014 | Volume: 51 | Issue: 1 | Pages: 52-56

10.1111/ppc.12065 | PMID 24605762 Get It

Signalling protein complexes isolated from primary human skin‐resident T cells can be analysed by Multiplex IP‐FCM
Smith, Stephen , Neier, Steven C. , Davis, Tessa R. , Pittelkow, Mark R. , Gil, Diana , Schrum, Adam G. , Smith, Stephen E P, Schrum, Adam G

Mayo Clinic

Experimental Dermatology | March 3, 2014 | Volume: 23 | Issue: 4 | Pages: 272-273

10.1111/exd.12362 | PMID 24588717 Get It

AbstractStudying signal transduction in skin‐resident T cells (sr‐T cells) can be limited by the small size of clinical biopsies. Here, we isolated sr‐T cells from clinical samples and analysed signalling protein complexes by multiplex immunoprecipitation detected by flow cytometry (mIP‐FCM). In samples from two independent donors, antigenic stimulation induced signalling proteins to join shared complexes that were observed in seven pairwise combinations among five proteins. This demonstrates that sr‐T cells isolated from small clinical samples provide sufficient material for mIP‐FCM‐based analysis of signalling‐induced protein complexes. We propose that this strategy may be useful for gaining improved mechanistic insight of sr‐T cell signal transduction associated with dermatological disease.
Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?
Zhang, Yuanhui , Mason, Jennifer, Smith, Steven A., Shah, Nilay D. , McCoy, Rozalina G. , Denton, Brian T.

Mayo Clinic

Diabetes Care | February 27, 2014 | Volume: 37 | Issue: 5 | Pages: 1338-1345

10.2337/dc13-1901 | PMID 24574345 Get It

OBJECTIVE While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. RESEARCH DESIGN AND METHODS We developed and validated a new population-based glycemic control Markov model that simulates natural variation in HbA1c progression. The model was calibrated using a U.S. data set of privately insured individuals diagnosed with type 2 diabetes. We compared treatment intensification of metformin monotherapy with sulfonylurea, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, or insulin. Outcome measures included life-years (LYs), quality-adjusted life-years (QALYs), mean time to insulin dependence, and expected medication cost per QALY from diagnosis to first diabetes complication (ischemic heart disease, myocardial infarction, congestive heart failure, stroke, blindness, renal failure, amputation) or death. RESULTS According to our model, all regimens resulted in similar LYs and QALYs regardless of glycemic control goal, but the regimen with sulfonylurea incurred significantly lower cost per QALY and resulted in the longest time to insulin dependence. An HbA1c goal of 7% (53 mmol/mol) produced higher QALYs compared with a goal of 8% (64 mmol/mol) for all regimens. CONCLUSIONS Use of sulfonylurea as second-line therapy for type 2 diabetes generated glycemic control and QALYs comparable with those associated with other agents but at lower cost. A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options.
Two‐year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial
Heck, Christianne, King‐Stephens, David , Nair, Dileep , Jobst, Barbara C. , Barkley, Gregory L., Salanova, Vicenta , Gwinn, Ryder P. , Skidmore, Christopher , Ness, Paul C. Van, Bergey, Gregory K. , Park, Yong D., Miller, Ian , Geller, Eric B., Rutecki, Paul , Zimmerman, Richard S. , Spencer, David , Leiphart, James W., Wharen, Robert E. , Fessler, James, Fountain, Nathan B. , Eisenschenk, Stephan, Duckrow, Robert B., Hirsch, Lawrence J. , Bazil, Carl W., O’Donovan, Cormac A. , Sun, Felice T., Courtney, Tracy A., Seale, Cairn G. , Morrell, Martha J. , Massey, Andrew D. , Cole, Andrew J. , Smith, Michael C. F. , Goldman, Alica M. , Edwards, Jonathan , Worrell, Gregory A. , Gross, Robert E. , Fountain, Nathan , Hirsch, Lawrence J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | February 24, 2014 | Volume: 55 | Issue: 3 | Pages: 432-441

10.1111/epi.12534 | PMID 24621228 Get It

Summary Objective To demonstrate the safety and effectiveness of responsive stimulation at the seizure focus as an adjunctive therapy to reduce the frequency of seizures in adults with medically intractable partial onset seizures arising from one or two seizure foci. Methods Randomized multicenter double‐blinded controlled trial of responsive focal cortical stimulation (RNS System). Subjects with medically intractable partial onset seizures from one or two foci were implanted, and 1 month postimplant were randomized 1:1 to active or sham stimulation. After the fifth postimplant month, all subjects received responsive stimulation in an open label period ( OLP ) to complete 2 years of postimplant follow‐up. Results All 191 subjects were randomized. The percent change in seizures at the end of the blinded period was −37.9% in the active and −17.3% in the sham stimulation group (p = 0.012, Generalized Estimating Equations). The median percent reduction in seizures in the OLP was 44% at 1 year and 53% at 2 years, which represents a progressive and significant improvement with time (p < 0.0001). The serious adverse event rate was not different between subjects receiving active and sham stimulation. Adverse events were consistent with the known risks of an implanted medical device, seizures, and of other epilepsy treatments. There were no adverse effects on neuropsychological function or mood. Significance Responsive stimulation to the seizure focus reduced the frequency of partial‐onset seizures acutely, showed improving seizure reduction over time, was well tolerated, and was acceptably safe. The RNS System provides an additional treatment option for patients with medically intractable partial‐onset seizures.
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update
Smith, Norm D. , Castle, Erik P., Gonzalgo, Mark L. , Svatek, Robert S. , Weizer, Alon Z. , Montgomery, Jeffrey S., Pruthi, Raj S. , Tollefson, Matthew K. , Konety, Badrinath R. , Shabsigh, Ahmad , Krupski, Tracey L. , Barocas, Daniel A. , Dash, Atreya , Kibel, Adam S. , Parekh, Dipen J. , Woods, Michael E. , Quek, Marcus Lee

Mayo Clinic

BJU International | February 24, 2014 | Volume: 115 | Issue: 2 | Pages: 198-205

10.1111/bju.12699 | PMID 25626182 Get It

The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy ( ORC ) vs robot‐assisted RC ( RARC ), pelvic lymph node dissection ( PLND ) and urinary diversion for oncological outcomes, complications and health‐related quality of life ( HRQL ) measures with a primary endpoint of 2‐year progression‐free survival ( PFS ). RAZOR is a multi‐institutional, randomized, non‐inferior, phase III trial that will enrol at least 320 patients with T 1– T 4, N 0– N 1, M 0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics ( CRAB ) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T 1– T 4, N 0– N 1, M 0 patients with bladder cancer to ORC vs RARC , PLND and urinary diversion. RAZOR is a multi‐institutional, non‐inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2‐year PFS . Full data from the RAZOR trial are not expected until 2016–2017.
Preventive PCI versus culprit lesion stenting during primary PCI in acute STEMI: a systematic review and meta-analysis
Pandit, Anil , Aryal, Madan Raj , Pandit, Aashrayata Aryal, Hakim, Fayaz A., Mainali, Naba Raj , Lee, Howard R., Fortuin, F. David , Mookadam, Farouk , Aryal Pandit, Aashrayata, Hakim, Fayaz Ahmad, Sharma, Prashant , Giri, Smith , Sharma, Prashant Kumar , Mookadam, Farouk

Mayo Clinic

Open Heart | February 18, 2014 | Volume: 1 | Issue: 1 | Pages: e000012

10.1136/openhrt-2013-000012 | PMID 25332779 Get It

Aim The benefit of preventive percutaneous coronary intervention (PCI) in ST elevation myocardial infarction (STEMI) has been shown in randomised trials. However, all the randomised trials are underpowered to detect benefit in cardiac death. We aim to systematically review evidence on the cardiac mortality benefit of preventive PCI in patients presenting with acute STEMI in randomised patient populations. Methods PubMed, Scopus, Cochrane and clinicaltrials.gov databases were searched for studies published until 30 September 2013. The studies were limited to randomised clinical trials. Independent observers abstracted the data on outcomes, characteristics and qualities of studies included. Fixed effect model was employed for meta-analysis. Heterogeneity of studies included was analysed using I2 statistics. Results In three randomised clinical trials published, involving 748 patients with acute STEMI and multivessel disease, 416 patients were randomised to preventive PCI and 332 to culprit-only PCI. Patients undergoing preventive PCI had significant lower risk of cardiovascular deaths (pooled OR 0.39, 95% CI 0.18 to 0.83, p=0.01, I2=0%), repeat revascularisation (pooled OR 0.28, 95% CI 0.18 to 0.44, p=0.00001, I2=0%) and non-fatal myocardial infarction (pooled OR 0.38, 95% CI 0.20 to 0.75, p=0.005, I2=0%) compared with culprit-only revascularisation. Conclusions In patients presenting with acute STEMI and significant multivessel coronary artery disease, based on our data, preventive PCI is associated with lower risk of cardiovascular mortality compared with primary PCI of only the culprit artery. This finding needs to be confirmed in larger adequately powered randomised clinical trials.
Consensus treatment of medication overuse headache in Latin America and Europe
Schwedt, Todd J. , Smith, Jonathan H. , Schwedt, Todd J

Mayo Clinic

Cephalalgia | February 12, 2014 | Volume: 34 | Issue: 9 | Pages: 643-644

10.1177/0333102414521512 | PMID 24523430 Get It

A selected group of large common fragile site genes have decreased expression in oropharyngeal squamous cell carcinomas
Kasperbauer, Jan L. , Tombers, Nicole M. , Wang, Vivian , Mayer, Kevin , Smith, David I., Gao, Ge , Smith, David I.

Mayo Clinic

Genes, Chromosomes and Cancer | January 31, 2014 | Volume: 53 | Issue: 5 | Pages: 392-401

10.1002/gcc.22150 | PMID 24481768 Get It

The common fragile sites (CFSs) are large regions of profound genomic instability found in all individuals. The frequent deletions and other alterations in these regions in multiple cancers has led to the discovery of a number of extremely large genes contained within these regions and several of the large CFS genes have already been demonstrated to function as tumor suppressors involved in the formation of many different cancers. To study the large CFS genes in oropharyngeal squamous cell carcinoma (OPSCC), we did RNA seq analysis from 11 head and neck cancer patients. This revealed that there are six large CFS genes which consistently had decreased expression in the tumor samples compared to their matched normal tissues. These six genes are PARK2, DLG2, NBEA, CTNNA3, DMD, and FHIT. PARK2 and FHIT are located within the two most frequently expressed CFSs and both have been demonstrated to function as tumor suppressors, while the other large genes are found to have frequent alterations in multiple cancers. Validation experiments using real time PCR indicated that over 60% of OPSCC tumors showed decreased expression for all six genes. Both HPV‐positive and HPV‐negative OPSCCs had similar proportions with loss of expression of these genes. Our results suggest that this selected group of large genes might serve as potential tumor suppressors involved in the development of OPSCCs. Further studies are needed to investigate whether the decreased expression observed is due to genomic instability within the CFS regions or the selection for alterations of specific large CFS genes. © 2014 Wiley Periodicals, Inc.
Right Atrial Appendage Aneurysm: A Systematic Review
Aryal, Madan Raj , Hakim, Fayaz A., Ghimire, Sushil , Pandit, Anil , Bhandari, Yashoda, Acharya, Yam Prasad, Pradhan, Rajesh , Giri, Smith

Mayo Clinic

Echocardiography | January 22, 2014 | Volume: 31 | Issue: 4 | Pages: 534-539

10.1111/echo.12510 | PMID 24447323 Get It

BackgroundRight atrial appendage aneurysm (RAAA) is rare with fewer than 20 cases reported in the literature. We sought to systematically review the published cases of RAAA in terms of demographics, clinical characteristics, treatment, complications, and outcome.MethodologyElectronic search for case reports, case series, and related articles published until July 2013 was carried out and clinical data were extracted and analyzed.ResultsSeventeen cases of RAAA were identified with equal sex distribution and commonly presenting in the third decades of life. Dyspnea and palpitation were the most common clinical presentations. Echocardiography was the most common diagnostic modality. The mean size of aneurysm was 8.83 ± 4.84 × 6.05 ± 2.99 cm. Most of the patients were treated medically with close follow‐up. The mean follow‐up period was 10 months. Atrial tachyarrhythmias and heart failure were the most common complications.ConclusionRight atrial appendage aneurysm although rare may be associated with significant morbidity. Surgical resection is indicated in symptomatic patients.